Octave Life Sciences
3
69M
2
1
0.33
- Stages of investment
- Areas of investment
Summary
Besides, a startup needs to be aged 2-3 years to get the investment from the fund. Among the most popular fund investment industries, there are Health Care, Biotechnology. Among the most popular portfolio startups of the fund, we may highlight Neuraly.
The typical case for the fund is to invest in rounds with 7 participants. The meaningful sponsors for the fund in investment in the same round are Smilegate Investment, Magna Investment, LB Investment.
The high activity for fund was in 2018. The usual things for fund are deals in the range of 50 - 100 millions dollars. The fund is constantly included in less than 2 deals per year.
Investments analytics
Analytics
- Total investments
- 3
- Lead investments
- 1
- Follow on index
- 0.33
- Investments by industry
- Pharmaceutical (2)
- Biotechnology (1)
- Health Care (1)
- Investments by region
-
- South Korea (2)
- United States (1)
- Peak activity year
- 2018
Discover reliable insights
Leverage validated data, identify key contacts and secure funding opportunities for your business.Quantitative data
- Avg. startup age at the time of investment
- 7
- Avg. valuation at time of investment
- 261M
- Group Appearance index
- 1.00
Need more data?
Get access to full data about investors, including their team, contact information, and historic data.
Latest deals
| Company name | Deal date | Industry | Deal stage | Deal size | Location |
|---|---|---|---|---|---|
| D&D Pharmatech | 14 Aug 2019 | Pharmaceutical | Early Stage Venture | 137M | Gyeonggi-do, Seongnam-si, South Korea |
At Unicorn Nest, we combine cutting-edge technology with human expertise to build one of the most reliable venture capital databases in the market. Our process begins with automated AI-enhanced data collection, leveraging the full potential of Large Language Models (LLMs).
Later, our team of analysts takes it further with manual verification, using proprietary tools for data cleaning and validation to ensure accuracy and reliability. We cross-check and enhance our findings through press and media monitoring, integrating information from trusted news outlets and venture capital aggregators. Finally, we stay ahead of the curve by monitoring social networks like LinkedIn and X.com.